HUNTINGTON BEACH, Calif., Jan. 8, 2013 /PRNewswire/ -- Absorption Pharmaceuticals, makers of the world's first FDA-Approved topical treatment for premature ejaculation, Promescent, announced today that Laurence A. Levine, MD will assume the role of Chief Medical Officer (CMO). Dr. Levine will oversee the company's growth and education efforts, with a focus on getting Promescent written into protocols as a top-line treatment for premature ejaculation nationwide. "We're thrilled to have such a highly respected and knowledgeable physician join our team," says Jeff Abraham, CEO of Absorption Pharmaceuticals. "We have been growing rapidly due to Promescent's proven effectiveness and securing Dr. Levine– whom has already provided invaluable assistance in reaching key opinion leaders in sexual medicine– adds to the credibility of this revolutionary product in the sexual medicine category. We look forward to the ongoing adoption of Promescent as the primary medical solution for premature ejaculation." Dr. Levine received his medical degree from the University of Colorado Medical School, followed by a residency in general surgery at Tufts-New England Medical Center and in urology at the Harvard Program in Urology at Brigham and Women's Hospital in Boston. He has made a substantial contribution to the medical press in the form of peer-reviewed articles, books, book chapters, and Internet publications regarding male sexual dysfunction, fertility, chronic orchialgia and reconstructive urology. Currently, Dr. Levine is a professor of urology at the Rush University Medical Center in Chicago, and is in private practice with Uropartners, LLC. He has received multiple awards and honors; and served as a past-president of the Sexual Medicine Society of North America and the Chicago Urological Society. "I am very excited to join Absorption Pharmaceuticals as Chief Medical Officer," says Dr. Levine. "Promescent is a ground-breaking, unrivaled product and doctors across the country are delighted to have a solution to a problem that previously has not received the attention it deserves. As an early adopter of the product as treatment for my patients with PE, I'm proud to lead the charge in spreading awareness of Promescent to the medical community."